Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose escalation and expansion of BI 1831169 plus anti-PD-1 antibody in Japanese patients with advanced/metastatic solid tumours
jRCT2033250370Phase 1Suspended
- Sponsor
- Nippon Boehringer Ingelheim
- Start
- Oct 2025
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of VSV-GP in Nonhematologic neoplasms, sponsored by Nippon Boehringer Ingelheim. Primary endpoint: Occurrence of dose limiting toxicities (DLTs) during the maximum tolerated dose (MTD) evaluation period. Started Oct 2025; status: suspended.
02
Drugs
VSV-GP
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2033250370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033250370.